In an effort to better track the health impacts of hemp-derived cannabinoid products in the U.S., the Food and Drug Administration (FDA) is proposing that CBD and other hemp-derived cannabinoids be added as selectable options on federal documents used by healthcare professionals, patients and consumers to report adverse events.